Abacavir/Lamivudine Versus Tenofovir/Emtricitabine in Virologically Suppressed Patients Switching from Ritonavir-Boosted Protease Inhibitors to Raltegravir

MLA

Ignacio Pérez, et al. Abacavir/Lamivudine Versus Tenofovir/Emtricitabine in Virologically Suppressed Patients Switching from Ritonavir-Boosted Protease Inhibitors to Raltegravir. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....5e8ea486bddd6de10b51037f744415da&authtype=sso&custid=ns315887. Accessed 6 Jan. 2025.

APA

Ignacio Pérez, Esteban Martínez, Polyana M. d’Albuquerque, Judit Pich, & José M. Gatell. (n.d.). Abacavir/Lamivudine Versus Tenofovir/Emtricitabine in Virologically Suppressed Patients Switching from Ritonavir-Boosted Protease Inhibitors to Raltegravir.

Chicago

Ignacio Pérez, Esteban Martínez, Polyana M. d’Albuquerque, Judit Pich, and José M. Gatell. 2025. “Abacavir/Lamivudine Versus Tenofovir/Emtricitabine in Virologically Suppressed Patients Switching from Ritonavir-Boosted Protease Inhibitors to Raltegravir.” Accessed January 6. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....5e8ea486bddd6de10b51037f744415da&authtype=sso&custid=ns315887.